AIM
AIM ImmunoTech Inc.
stockNYSEAMERICAN
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.16 | 2026-10-29 | -3.60% | 0.901 |
| 1M | 0.19 | 2026-10-05 | -18.32% | 1.947 |
| 3M | 0.28 | 2026-08-05 | -45.27% | 1.415 |
| 6M | 0.52 | 2026-05-05 | -69.98% | 0.065 |
| 1Y | 1.79 | 2025-11-05 | -91.32% | 0.302 |
| 2Y | 0.25 | 2024-11-05 | -37.87% | — |
| 5Y | 1.77 | 2021-11-05 | -91.22% | -6.631 |
AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) stock price today is $0.16, and today's volume is 357,875. AIM is down 3.602% today. The 30 day average volume is 703,614. AIM market cap is $6.19M with 39.89M shares outstanding.